![Moa Fransson](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Fortuna: 4 036 $ al 31/05/2026
Moa Fransson is the founder of Bioflow Systems AB. Dr. Fransson is the Chief Executive Officer of Mesenkia Therapeutics AB since 2024, the Chief Executive Officer of Genagon Therapeutics AB since 2019, and the Director of Enzymatica AB since 2022.
Dr. Fransson holds a doctorate from the University of Uppsala.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
ENZYMATICA AB 0,01 % | 31/12/2024 | 13.652 ( 0,01 % ) | 4 036 $ | 31/05/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
| ENZYMATICA AB | Director/Miembro de la Junta | 01/05/2022 |
Genagon Therapeutics AB
 Genagon Therapeutics AB BiotechnologyHealth Technology Provides scientific and technical research and development services | Director Ejecutivo | 01/12/2019 |
| Empresas | Cargo | Fin |
|---|---|---|
Bioflow Systems AB | Fundador | - |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 4 |
|---|---|
University of Uppsala
 University of Uppsala Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Enzymatica AB
 Enzymatica AB Medical SpecialtiesHealth Technology Develops and sells medical technology products against infectious diseases | Health Technology |
Genagon Therapeutics AB
Genagon Therapeutics AB BiotechnologyHealth Technology Provides scientific and technical research and development services | Health Technology |
Bioflow Systems AB |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.
